REG - N4 Pharma PLC - Nanogenics Update

N4 PharmaAnnouncement

16/01/2024 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240116:nRSP7479Za&default-theme=true

RNS Number : 7479Z  N4 Pharma PLC  16 January 2024

16 January 2024

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Nanogenics Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to provide an update on its subsidiary, Nanogenics
Limited ("Nanogenics").

 

Nanogenics has signed a contract to start the formulation and sequence
selection work to prepare its ECP105 product for testing in pre-clinical
studies at Kings College, London.

 

Nanogenics' ECP105 product for the recovery of post-surgical treatment of
Glaucoma contains a proprietary siRNA sequence to silence the fibrotic gene
MRTF-B. Glaucoma patients who have failed to respond to medication need
surgery to lower intraocular pressure which causes fibrosis at the surgery
site. This fibrosis often leads to failure of the surgery and frequently
patients have to undergo further surgery. ECP105 is intended for injection
into the ocular cavity to switch off the gene responsible for the fibrosis.
Unlike current off-label treatment using toxic chemotherapy drugs, ECP105 is
intended for repeat use to prevent the need for further surgery.

 

The work involves creating and testing a novel formulation containing
Nanogenics' proprietary siRNA sequence to undertake a proof of concept in-vivo
study, to demonstrate that a single dose of its Glaucoma surgery treatment
ECP105 can match the anti-fibrotic effect of current post surgical treatment
using Mitomycin C, but without the cytotoxic side effects seen with this
approach.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are very excited for the potential of ECP105, which is a unique product
for an unmet clinical need in the ophthalmology market. More than 75 million
people worldwide are affected by Glaucoma and the total Glaucoma treatment
market size in 2021 exceeded $5.5 billion and is growing. A novel product in
this space alone represents a good opportunity for Nanogenics and importantly
the antifibrotic siRNA sequence can also be used to investigate other fibrotic
treatments for liver and lung fibrosis."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub            Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit                                          https://investors.n4pharma.com/link/GyVdGr
                                                              (https://investors.n4pharma.com/link/GyVdGr)
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                             Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBAMFTMTTBBFI